WO2001044266A3 - Nucleic acid compounds and screening assays using the same - Google Patents

Nucleic acid compounds and screening assays using the same Download PDF

Info

Publication number
WO2001044266A3
WO2001044266A3 PCT/GB2000/004862 GB0004862W WO0144266A3 WO 2001044266 A3 WO2001044266 A3 WO 2001044266A3 GB 0004862 W GB0004862 W GB 0004862W WO 0144266 A3 WO0144266 A3 WO 0144266A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
same
acid compounds
screening assays
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/004862
Other languages
French (fr)
Other versions
WO2001044266A2 (en
Inventor
Jonathan Karn
Stephen Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis Cambridge Ltd
Original Assignee
Ribotargets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9929820.0A external-priority patent/GB9929820D0/en
Application filed by Ribotargets Ltd filed Critical Ribotargets Ltd
Priority to CA002391814A priority Critical patent/CA2391814A1/en
Priority to EP00985610A priority patent/EP1237899A2/en
Priority to AU22018/01A priority patent/AU2201801A/en
Publication of WO2001044266A2 publication Critical patent/WO2001044266A2/en
Publication of WO2001044266A3 publication Critical patent/WO2001044266A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a compound comprising nucleotide sequences: -5'-P-N?1-N2-G-N3¿-C-I-3' and 3'-Q-N?4-N5-N6-N7-N8-N9¿-Y-J-5' wherein P and Q are any two nucleotides that can form a Watson-Crick base pair, I and J are any two nucleotides that can form a base pair, N?1 and N4¿ are not both C, when N2 is A, N7 is not G, N9 can only be U if N3 is A, when N3 is G, N9 is A, and wherein said sequences are capable of annealing, characterised in that said compound comprises 200 or fewer nucleotides.
PCT/GB2000/004862 1999-12-16 2000-12-18 Nucleic acid compounds and screening assays using the same Ceased WO2001044266A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002391814A CA2391814A1 (en) 1999-12-16 2000-12-18 Assays
EP00985610A EP1237899A2 (en) 1999-12-16 2000-12-18 Nucleic acid compounds and screening assays using the same
AU22018/01A AU2201801A (en) 1999-12-16 2000-12-18 Assays

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9929820.0 1999-12-16
GBGB9929820.0A GB9929820D0 (en) 1999-12-16 1999-12-16 Assay
US17180499P 1999-12-22 1999-12-22
US60/171,804 1999-12-22

Publications (2)

Publication Number Publication Date
WO2001044266A2 WO2001044266A2 (en) 2001-06-21
WO2001044266A3 true WO2001044266A3 (en) 2001-12-20

Family

ID=26316129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004862 Ceased WO2001044266A2 (en) 1999-12-16 2000-12-18 Nucleic acid compounds and screening assays using the same

Country Status (4)

Country Link
EP (1) EP1237899A2 (en)
AU (1) AU2201801A (en)
CA (1) CA2391814A1 (en)
WO (1) WO2001044266A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851449B2 (en) 2013-07-03 2023-12-26 Takeda Pharmaceutical Company Limited Heterocyclic amide compounds having an RORvt inhibitory action

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027383A1 (en) * 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor or at least one neuropeptide
WO2003018747A2 (en) * 2001-08-22 2003-03-06 Isis Pharmaceuticals, Inc. Molecular interaction sites of hepatitis c virus rna and methods of modulating the same
FR2848572B1 (en) * 2002-12-12 2005-12-09 Univ Joseph Fourier INHIBITOR MOLECULES OF PROTEIN SYNTHESIS OF HEPATITIS C VIRUS AND METHOD FOR SCREENING THESE INHIBITORY MOLECULES
JP4545091B2 (en) * 2003-01-24 2010-09-15 財団法人 東京都医学研究機構 Oligoribonucleotide or peptide nucleic acid that inhibits the function of hepatitis C virus
GB0302113D0 (en) * 2003-01-29 2003-03-05 Medical Res Council Ires
FR2974805B1 (en) 2011-05-02 2013-05-10 Isp Investments Inc NOVEL MODULATING PEPTIDES OF THE TRF-2 PROTEIN AND COMPOSITIONS COMPRISING THEM
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6427491B2 (en) 2013-07-03 2018-11-21 武田薬品工業株式会社 Heterocyclic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009342A1 (en) * 1995-09-08 1997-03-13 Scriptgen Pharmaceuticals, Inc. Screen for compounds with affinity for rna
US5922857A (en) * 1992-09-28 1999-07-13 Chiron Corporation Methods and compositions for controlling translation of HCV proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922857A (en) * 1992-09-28 1999-07-13 Chiron Corporation Methods and compositions for controlling translation of HCV proteins
WO1997009342A1 (en) * 1995-09-08 1997-03-13 Scriptgen Pharmaceuticals, Inc. Screen for compounds with affinity for rna

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL EBI; 30 October 1998 (1998-10-30), MICHALEK ET AL.: "Hordeum vulgare genomic DNA fragment; clone MWG0065.rev", XP002178313 *
SIZOVA ET AL.: "Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis c virus and classical swine fever virus RNAs", JOURNAL OF VIROLOGY, vol. 72, no. 6, June 1998 (1998-06-01), pages 4775 - 4782, XP000993423 *
WALLIS ET AL.: "In vitro selection of a viomycin-binding RNA pseudoknot", CHEMISTRY AND BIOLOGY, vol. 4, no. 5, 1997, pages 357 - 366, XP001024489 *
WANG Y ET AL: "Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 36, 1997, pages 768 - 779, XP002120808, ISSN: 0006-2960 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851449B2 (en) 2013-07-03 2023-12-26 Takeda Pharmaceutical Company Limited Heterocyclic amide compounds having an RORvt inhibitory action

Also Published As

Publication number Publication date
AU2201801A (en) 2001-06-25
WO2001044266A2 (en) 2001-06-21
EP1237899A2 (en) 2002-09-11
CA2391814A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
AU2001268513A1 (en) Nucleic acid accessible hybridization sites
AU2001273548A1 (en) Photoselection of nucleic acid ligands
CA2283509A1 (en) Novel bicyclonucleoside and oligonucleotide analogue
HUP0003600A3 (en) Nucleic acid molecules from artichoke (cynara scolymus) encoding enzymes having fructosyl polymerase activity
AU2002365811A1 (en) Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations
AU4332399A (en) Rna polymerase chain reaction
WO2000040525A3 (en) Polymer arrays and methods of making and using same
AU2001278061A1 (en) Triphosphate oligonucleotide modification reagents and uses thereof
CA2438574A1 (en) Method of detecting nucleotide polymorphism
AU2001241674A1 (en) Variant galactose oxidase, nucleic acid encoding same, and methods of using same
WO2001044266A3 (en) Nucleic acid compounds and screening assays using the same
IL136349A0 (en) Virulence-associated nucleic acid sequences and uses thereof
AU2002352902A1 (en) Thermus thermophilus nucleic acid polymerases
EP1047773A4 (en) CUBILIN PROTEIN, DNA SEQUENCES ENCODING CUBILIN, AND USES THEREOF
AU2002346517A1 (en) Thermus oshimai nucleic acid polymerases
DE69833112D1 (en) Rna polymerase
IL139750A0 (en) Poly (adp-ribose) polymerase gene
AU4942597A (en) Thermostable dna polymerase from (anaerocellum thermophilum)
AU1981295A (en) Novel protein-kinase, nucleic acid sequences encoding the same and methods related thereto
EP0622464A3 (en) Nucleic acid assay procedure.
EP1300473A4 (en) Method of detecting nucleotide polymorphism
AU2002219230A1 (en) Method for the determination of at least one functional polymorphism in the nucleotide sequence of a preselected candidate gene and its applications
AU8002300A (en) Telomerase reverse transcriptase (tert) genes
AU2002350247A1 (en) Thermus igniterrae nucleic acid polymerases
WO2001058914A3 (en) Haplotypes of the interleukin 15 gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2391814

Country of ref document: CA

Ref document number: 22018/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000985610

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000985610

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000985610

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP